CordenPharma Expands Lipid Supply for Moderna
CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.
CordenPharma announced on May 28, 2020 an amendment to an existing manufacturing agreement with Moderna, Inc. that enables CordenPharma to manufacture large-scale volumes of Moderna’s lipid excipients to be used in the manufacture of Moderna’s vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).
The agreement expands a lipids manufacturing agreement originally signed in 2016 between Moderna and CordenPharma Switzerland to include CordenPharma Chenôve (France) and CordenPharma Colorado. The agreement will begin immediately to meet Moderna’s increasing demand to scale manufacturing of their vaccine candidate.
Source: CordenPharma
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
